| Description | The introduction of Poly A tail at the 3'end of mRNA by tailing enzyme can increase the stability of mRNA and increase the efficiency of mRNA translation. The advantage of using the tailing enzyme to introduce the Poly A tail is that it is simple and easy to implement, avoiding the instability of The introduction of Poly A tail at the 3'end of mRNA by tailing enzyme can increase the stability of mRNA and increase the efficiency of mRNA translation. The advantage of using the tailing enzyme to introduce the Poly A tail is that it is simple and easy to implement, avoiding the instability of the plasmid caused by the introduction of too many consecutive T bases during plasmid construction.E. coli Poly (A) Polymerase does not rely on the presence of a template, and can catalyze the incorporation of ATP into the 3´ end of RNA in the form of AMP, that is, a poly A tail is added to the 3´ end of RNA. Poly (A) polymerase has a high tailing efficiency and can add 20~200 A bases to the 3´ end of RNA. Poly (A) structure helps to improve the translation efficiency of mRNA.This product is expressed in large-scale fermentation using Escherichia coli, is produced with medicinal specifications of raw materials, and strictly controls host protein residues, nucleic acid residues, etc., and conforms to GMP standard product production and quality management procedures to ensure that the production process and all raw materials can be traced.Quality requirements Project Standard Method Exterior Clear liquid Visual inspection Visible foreign body Compliance Chinese Pharmacopoeia 2020 Edition Fourth Part 1 Lamp Inspection Method (General Rule 0904) pH value 7.0-8.0 Chinese Pharmacopoeia 2020 Edition Part IV pH Determination Method (General Principle 0631) Active 4.9KUml-5.1KU/ml Tailing modification and efficiency determination method Purity ≥95% Chinese Pharmacopoeia 2020 Edition Part IV High Performance Liquid Chromatography (General Principle 0512) Endonuclease residue 004-DNA degradation does not exceed 10% Incubate SU enzyme with 004-DNA.37C for 3h Exonuclease residue 019 HindⅢ-DNA degradation does not exceed 10% Incubate SU enzyme with 019 HindⅢ-DNA at 37°C for 3h RNase residue Degradation of 293-RNA does not exceed 10% 5U enzyme and 293-RNA. Incubate at 37°C for 1h Bacterial endotoxin content ≤10 EU/mg Chinese Pharmacopoeia 2020 Edition Fourth Gel Limit Test Method (General Rule 1143) Host DNA residue ≤100 pg/mg Fluorescence quantitative PCR Host protein residue ≤50 ppm Chinese Pharmacopoeia 2020 Edition Part IV Method for the Determination of Bacterial Protein Residues (General Rule 3412) Mycoplasma Feminine Mycoplasma detection kit Heavy metal residue ≤10 ppm Chinese Pharmacopoeia 2020 Edition Fourth Heavy Metal Inspection Method (General Principle 0821) Follow the following specifications for production1. ISO 9001:2015, certified facility.2. "GMP Appendix-Cell Therapy Products" State Drug Administration.3. "General Introduction to Human Gene Therapy-Chinese Pharmacopoeia 2020" National Pharmacopoeia Commission.4. USP Chapter <1043>, Ancillary Materials for Cell, Gene, and Tissue-Engineered Products are used as excipients in cell therapy, gene therapy and tissue engineering products.5. USP Chapter <92>, Growth Factors and Cytokines Used in Cell Therapy Manufacturing Cytokines and growth factors used in the production of cell therapy products.6.Ph. Eur. General Chapter 5.2.12, Raw Materials of Biological Origin for the Production of Cell-based and Gene Therapy Medicinal Products.Product Usage1. Used for RNA 3´ end labeling.2. Add Poly(A) tail to RNA for cloning or affinity purification. For example, adding Poly (A) to miRNA provides an oligo-dT primer binding site for cDNA synthesis.3. Improve the translation efficiency of RNA in eukaryotic cells.Preservation system20mM Tris-HCl; 300mM NaCl; 1mM DTT; 1mM EDTA; 0.1% TritonX-100; 50% (v/v) Glycerol, pH 7.5.ApplicationsThe intact mRNA expresses GFP protein in the cell, the capping enzyme is compared with the cap analogPrecautions1. Thermal inactivation conditions: 65°C, 20 min.2. The enzyme can only use RNA as a substrate.3. The enzyme adds AMP to the 3´ end of RNA with high selectivity, and does not add the same length of Poly (A) to all RNA molecules.4. The enzyme uses M-MuLV reverse transcriptase reaction buffer, which can also be used for reaction.5. The enzyme requires divalent cations such as Mg2+ to be active.6. The length of RNA plus A tail is affected by the amount of enzyme, ATP, reaction time and other factors. The amount of A required for different experiments will be different. The length of A can be adjusted by reducing the reaction time. The enzyme is at 37°C. About 30 A bases can be added in 30 minutes of reaction, and about 100 A bases can be added in 1 hour.7. EDTA inhibits the enzyme activity. If the reaction is stopped, it can be purified directly by adding EDTA to a final concentration of 10mM... Read More | Inquire | Purity: >90%, by SDS-PAGE visualized with Coomassie® Blue Staining.Description：CNN1 is a member of the calponin family. CNN1 is a thin filament-associated protein which is involved in the regulation and modulation of smooth muscle contraction. CNN1 is able to bind to actin, calmodulinPurity: >90%, by SDS-PAGE visualized with Coomassie® Blue Staining.Description：CNN1 is a member of the calponin family. CNN1 is a thin filament-associated protein which is involved in the regulation and modulation of smooth muscle contraction. CNN1 is able to bind to actin, calmodulin, troponin C and tropomyosin. Prevention of actomyosin Mg-ATPase activity is a result of interaction between calponin and actin... Read More | Purity: >95%, by SDS-PAGE visualized with Coomassie® Blue Staining. Description： CD4, also known as L3T4, T4, and W3/25, is an approximately 55 kDa type I transmembrane glycoprotein that is expressed predominantly on thymocytes and a subset of mature T lymphocytes. It is a standard Purity: >95%, by SDS-PAGE visualized with Coomassie® Blue Staining. Description： CD4, also known as L3T4, T4, and W3/25, is an approximately 55 kDa type I transmembrane glycoprotein that is expressed predominantly on thymocytes and a subset of mature T lymphocytes. It is a standard phenotype marker for the identification of T cell populations. Mature human CD4 consists of a 371 amino acid (aa) extracellular region containing four immunoglobulin-like domains, a 22 aa transmembrane segment, and a 40 aa cytoplasmic domain. Within the ECD, human CD4 shares approximately 52% aa sequence identity with mouse and rat CD4. CD4 is expressed along with CD8 on double positive T cells during their development in the thymus. Either CD4 or CD8 expression is then lost, giving rise to single positive (SP) CD4+ or CD8+ mature T cells. CD4+ SP cells, also known as T helper cells, further differentiate into multiple subsets of CD4+ cells including Th1, Th2, Th17, Tfh, and Treg cells which regulate humoral and cellular immunity. CD4 is reexpressed on circulating CD8+ T cells upon activation and contributes to their cytotoxic effector activity. In human, CD4 is additionally expressed on macrophages, neutrophils, monocytes, NK cells, and neurons and glial cells in the brain. Similar CD4 distribution between species cannot be assumed as demonstrated by its presence on macrophages in human and rat but not in mouse. CD4 binds directly to MHC class II molecules on antigen presenting cells. This interaction contributes to the formation of the immunological synapse which is focused around the TCR-MHC class II-antigenic peptide interaction. Palmitoylation of two cysteine residues in the cytoplasmic tail of CD4 promotes the localization of CD4 in lipid rafts and its ability to augment TCR signaling via activation of the tyrosine kinase Lck. CD4 also functions as a chemotactic receptor for IL-16 and, in human, as a co-receptor for the gp120 surface glycoprotein of HIV-1... Read More | Purity: >90%, by SDS-PAGE visualized with Coomassie® Blue Staining. Description: Major histocompatibility complex, class II, DR alpha (HLA-DRA) belongs to the MHC class II family. HLA-DRA binds peptides derived from antigens which access the endocytic route of antigen presenting cells (APC) Purity: >90%, by SDS-PAGE visualized with Coomassie® Blue Staining. Description: Major histocompatibility complex, class II, DR alpha (HLA-DRA) belongs to the MHC class II family. HLA-DRA binds peptides derived from antigens which access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for identification by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mainly by degradation of proteins which access the endocytic route, where they are processed by lysosomal proteases and other hydrolases... Read More |